Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies - Episode 15
Comparing Afami-Cel Outcomes With Chemotherapy and Other Treatment Options
A panelist discusses how afamitresgene autoleucel (afami-cel) has shown encouraging response rates and durability of response in a heavily pretreated population where standard chemotherapy typically yields limited benefit, though direct comparisons are challenging because of the lack of randomized trials and the distinct patient populations treated with different therapeutic approaches.
Video content above is prompted by the following:
- How does afami-cel’s outcomes compare with chemotherapy, other immunotherapies, and investigational agents?
Related Content:
